Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.38 USD | -3.26% | -13.93% | -29.88% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.88% | 2.06B | B- | ||
+43.36% | 54.63B | B- | ||
-5.31% | 39.92B | B | ||
+37.52% | 38.82B | A | ||
+14.75% | 26.86B | B- | ||
-12.56% | 26.22B | C | ||
-22.45% | 18.78B | B | ||
+25.12% | 12.21B | B+ | ||
+0.04% | 12.16B | B+ | ||
+26.04% | 11.94B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NTLA Stock
- Ratings Intellia Therapeutics, Inc.